Loss Narrows. Alto Neuroscience, Inc. (NYSE: ANRO) reported a loss of $2.19 per share for fiscal 2025, narrower than $2.50 per share last year. The biotechnology company’s operating loss totaled $66.4 million for the year. The company reported no revenue.
Pre-revenue biotech trajectory. Alto Neuroscience remains in the clinical development stage with no commercial products generating sales. Revenue has held at zero across the trailing four quarters. The $691.5 million market capitalization reflects investor expectations for the company’s neuroscience pipeline rather than current commercial operations.
Analyst sentiment remains constructive. Despite the loss, the analyst community maintains a bullish stance with 9 Buy ratings and 1 Hold rating among the 10 analysts covering the stock. Shares closed at $22.23, near the 52-week high of $23.56 and well above the 52-week low of $1.60. Trading volume reached 250,901 shares.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.